# **Membranoproliferative GN (MPGN)/C3GN**
## **Overview**
## **Pathophysiology**
## **Clinical Presentation**
## **Drugs and Disease Associated with MPGN/C3GN**
## **Definitions of Treatment Response**
## **Treatment**
## **Sources**
 * [C3 glomerulopathies general info](https://pmc.ncbi.nlm.nih.gov/articles/PMC10704907/)
 * [Developing Therapies for C3 Glomerulopathy](https://khi.asn-online.org/uploads/developing_therapies_for_c3_glomerulopathy__report.18.pdf)
 * [Efficacy and Safety of Iptacopan i nPatient w/C3 Glomerulopathy](https://www.sciencedirect.com/science/article/pii/S2468024924023222)
 * [Alternative Complement pathway inhibition w/iptacopan for treatment of C3G](https://pubmed.ncbi.nlm.nih.gov/36217526/)
 * [Phase 3 Trial of Pegcetacoplan fof Patient with C3G or IC-MPGN](https://journals.lww.com/jasn/pages/articleviewer.aspx?year=2024&issue=10001&article=00313&type=Fulltext)
 * [Safety and EFficacy of Pegcetacoplan](https://pmc.ncbi.nlm.nih.gov/articles/PMC10658235/)
 * [MMF in Combination w/Steroids for C3G Case series](https://pubmed.ncbi.nlm.nih.gov/29326307/)
 * [MMR in C3G and Pathogenic Drivers of the Disease](https://pubmed.ncbi.nlm.nih.gov/32816888/)
 * [C5 Convertase blockade in MPGN](https://www.sciencedirect.com/science/article/abs/pii/S0272638619301003)
 * [Safety and EFficacy of Avacopan in Patients w/C3G](https://pubmed.ncbi.nlm.nih.gov/39392695/)
